Listed

HCA Healthcare, Inc.: Form 10-Q for the period ended Mar 31, 2026

Filed with the SEC on Apr 29, 2026 and accepted by EDGAR at Apr 29, 2026, 16:02 ET.

Share

Management's discussion and analysis

As filed, 1,772 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

During each of January 2026 and January 2025, our Board of Directors authorized share repurchase programs, both of which were for up to $10 billion of our outstanding common stock. During the quarter ended March 31, 2026, we repurchased 3,156,569 shares of our common stock at an average price of $497.63 per share through market purchases pursuant to the January 2025 authorization (which was fully utilized during the first quarter of 2026) and the January 2026 authorization. At March 31, 2026, we had $9.179 billion of repurchase authorization available under the January 2026 authorization.

The following table provides certain information with respect to our repurchases of common stock from January 1, 2026 through March 31, 2026 (dollars in billions, except per share amounts).

Period Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs Approximate Dollar Value of Shares That May Yet Be Purchased Under Publicly Announced Plans or Programs
January 1, 2026 - January 31, 2026 1,369,014 $474.07 1,369,014 $10.101
February 1, 2026 - February 28, 2026 808,653 $518.54 808,653 $9.682
March 1, 2026 - March 31, 2026 978,902 $513.30 978,902 $9.179
Total for first quarter 2026 3,156,569 $497.63 3,156,569

28

On April 23, 2026, our Board of Directors declared a quarterly dividend of $0.78 per share on our common stock payable on June 30, 2026 to stockholders of record at the close of business on June 16, 2026. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to the final determination of our Board of Directors.

Market risk

As filed, 186 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The information called for by this item is provided under the caption “Market Risk” under Item 2, “Management’s Discussion and Analysis of Financial Condition and Results of Operations.”

Controls and procedures

As filed, 727 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

HCA’s management, with the participation of HCA’s chief executive officer and chief financial officer, has evaluated the effectiveness of HCA’s disclosure controls and procedures as of March 31, 2026. Based on that evaluation, HCA’s chief executive officer and chief financial officer concluded that HCA’s disclosure controls and procedures were effective as of March 31, 2026.

Changes in Internal Control Over Financial Reporting

During the period covered by this report, there have been no changes in our internal control over financial reporting that have materially affected or are reasonably likely to materially affect our internal control over financial reporting.

Risk factors

As filed, 448 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Reference is made to the factors set forth under the caption “Forward-Looking Statements” in Part I, Item 2 of this quarterly report on Form 10-Q and other risk factors described in our annual report on Form 10-K for the year ended December 31, 2025, which are incorporated herein by reference. There have not been any material changes to the risk factors previously disclosed in our annual report on Form 10-K for the year ended December 31, 2025.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2026-03-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2026-01-01 to 2026-03-31$19.11bnus-gaap:Revenues
Interest expense3 months2026-01-01 to 2026-03-31$584.0mus-gaap:InterestExpense
Income tax3 months2026-01-01 to 2026-03-31$430.0mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2026-01-01 to 2026-03-31$1.62bnus-gaap:NetIncomeLoss
Diluted EPS3 months2026-01-01 to 2026-03-31$7.15us-gaap:EarningsPerShareDiluted
Basic EPS3 months2026-01-01 to 2026-03-31$7.25us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2026-01-01 to 2026-03-31226,652,000 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow3 months2026-01-01 to 2026-03-31$2.01bnus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure3 months2026-01-01 to 2026-03-31$1.12bnus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Dividends paid3 months2026-01-01 to 2026-03-31$183.0mus-gaap:PaymentsOfDividends
Share repurchases3 months2026-01-01 to 2026-03-31$1.57bnus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2026-03-31$940.0mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2026-03-31$16.05bnus-gaap:AssetsCurrent
Total assetsAt period end2026-03-31$61.45bnus-gaap:Assets
Current liabilitiesAt period end2026-03-31$19.26bnus-gaap:LiabilitiesCurrent
Long-term debtAt period end2026-03-31$39.49bnus-gaap:LongTermDebtNoncurrent
Current portion of debtAt period end2026-03-31$8.53bnus-gaap:DebtCurrent
Shareholders' equityAt period end2026-03-31−$6.30bnus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001193125-26-191444. Last ingested by Listed: Nov 11, 2026, 03:15 ET. Listed shows no prices and gives no investment advice.